Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02408471 · ClinicalTrials.gov registry record · NA
Ascension® Post- Approval Study; PyroCarbon Metacarpophalangeal Total Joint Prosthesis
A NA study, sponsored by Smith & Nephew.
- Terminated
- Registry status
- NA
- Development phase
- 97
- Enrollment target
NCT02408471: Clinical Trial NA study, sponsored by Smith & Nephew.
NCT02408471 is a NA study that was terminated before completion, run by Smith & Nephew. The registered enrollment target is 97 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02408471, a NA study, was terminated before completion, sponsored by Smith & Nephew.
- TERMINATED
- Registry status
- NA
- Development phase
- 97 participants
- Enrollment target
Study Summary
This study is a non-randomized, consecutive enrollment, one-year post-approval study of patients who are treated with the Ascension® MCP.
Primary Outcome
Count of participants with a revision surgery.
Interventions
- DEVICE Ascension® MCP Finger Implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2002-06 |
| Est. Completion | 2015-01 |
| Phase | NA |
Why NCT02408471 stopped before completion
NCT02408471 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Ascension® MCP Finger Implant is the first listed.
NCT02408471 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02408471 about?
NCT02408471 is a clinical study titled "Ascension® Post- Approval Study; PyroCarbon Metacarpophalangeal Total Joint Prosthesis". This study is a non-randomized, consecutive enrollment, one-year post-approval study of patients who are treated with the Ascension® MCP.
What is the current status of trial NCT02408471?
This trial is currently terminated. It is a NA study. The enrollment target is 97 participants. The study started on 2002-06. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02408471?
The interventions under investigation include: Ascension® MCP Finger Implant (DEVICE).
Who is sponsoring clinical trial NCT02408471?
This trial is sponsored by Smith & Nephew, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02408471's enrollment target sits among peer trials
97 923rd of 2000 higher than 1,076 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia